Meridian Clinical Research, LLC
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leonard, Daniel
NCT05836012: Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Active, not recruiting
2/3
400
US, RoW
HIL-214, Placebo
HilleVax
Gastroenteritis
01/24
07/24
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants

Recruiting
2
121
US
Prevnar 13, AFX3772
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
NCT05655182: A Study of BLB-201 RSV Vaccine in Infants and Children

Recruiting
1/2
137
US
PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
Blue Lake Biotechnology Inc.
Respiratory Syncytial Virus Infections
09/24
12/24
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting
1c
63
US
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Meissa Vaccines, Inc.
Respiratory Syncytial Virus (RSV)
10/23
10/23

Download Options